TGFB1 and rheumatic heart disease: The reduction of angiotensin II production and the synergistic effect of bradykinin in ACEIs enhance its cardio-protection effect by directly reducing IL-33 binding to sST2 and through the inhibition of TGF-β/MAPK/Smad signaling in RHD progression (Figure 3).